Conclusions
The PD-1 inhibitor showed an acceptable toxicity profile and moderate
efficacy on NSCLC patients with chronic viral infection, but still has
the potential to increase the incidence of hepatitis.
Keywords : immune checkpoint inhibitors; A history of infection;
Non-small cell lung cancer; Programmed cell death-1